Table 2

Main study characteristics and findings from 51 studies that examined mHealth intervention for diabetes and hypertension treatment and management

CategoryNumber of studies (n, %)Study ID*
Country/setting
 Developed country
  USA13 (25.5)13, 17, 18, 20, 24, 28, 29, 34, 35, 45, 46, 48, 50
  England6 (11.8)5, 19, 22, 44, 47, 51
  Korea6 (11.8)10, 11, 14, 36, 40, 43
  Italy4 (7.8)16, 23, 27, 32
  Germany2 (3.9)15–38
  Israel2 (3.9)2–25
  Australia1 (2.0)30
  Belgium1 (2.0)26
  France1 (2.0)44
 Developing country
  China5 (9.8)8, 9, 26, 33, 49
  Iran3 (5.9)1, 7, 31
  Egypt1 (2.0)4
  India1 (2.0)12
  Honduras and Mexico1 (2.0)41
  Malaysia1 (2.0)3
  Turkey1 (2.0)6
  Poland1 (2.0)37
  South Africa1 (2.0)42
 Intervention time/duration
  ≤3 months11 (21.6)1, 4, 6, 7, 15, 17, 31, 33, 36, 38, 41
  3–6 months23 (45.1)3, 8–14, 20, 21, 23, 25–27, 30, 32, 37 39, 43, 48–51
  >6 months17 (33.3)2, 5, 16, 18, 19, 22, 24, 28, 29, 34, 35, 40, 42, 44–47
 Sample size
  <10017 (33.3)1, 2, 4, 6, 12, 20, 22, 25, 26, 30, 31, 36–38, 40, 48, 50
  100–50027 (52.9)3, 5, 7–11, 13–17, 19, 23, 24, 27, 28, 32–35, 39, 41, 43, 45, 49, 51
  >5007 (13.7)18, 21, 29, 42, 44, 46, 47
 Targeted patient
  T1DM7 (13.7)2, 23, 27, 30, 32, 38, 39
  T2DM28 (54.9)1, 3–16, 19–21, 24, 26, 28, 29, 33–37, 40
  T1DM and T2DM combined4 (7.8)18, 22, 25, 31
  T2DM and HTN combined1 (2.0)17
  HTN11 (21.6)41–51
Type and specific function of mHealth
 MPTMs
  Knowledge and tips5 (9.8)1, 4, 13, 40, 42
  Suggestions1 (2.0)42
  Reminder2 (3.9)4–42
  Medical consultations‡1 (2.0)42
  Feedback1 (2.0)30
 Telemedicine
  Knowledge and tips26 (51.0)3, 6, 8, 9, 14–16, 19–22, 24, 26, 29, 31, 32, 34, 38–41, 44–46, 49, 51
  Suggestions20 (39.2)2, 5, 10, 11, 16, 17, 19–21, 25–27, 31, 33, 34, 36, 41, 43, 46, 47
  Reminder5 (9.8)16, 24, 27, 44, 49
  Medical consultations17 (33.3)5, 11, 14, 15, 19, 24–29, 36, 37, 39, 45, 46, 48
  Data monitoring/collection/store/transmit27 (52.9)2, 5, 8–11, 14, 16, 17, 20, 22, 25, 29, 31, 33, 34, 37, 40, 41, 43–47, 51
  Feedback10 (19.6)2, 9, 10, 14, 22, 27, 31, 37, 38, 51
 MPCs
  Knowledge and tips3 (5.9)7, 18, 35
  Medical consultations3 (5.9)7, 18, 35
  Reminder1 (2.0)35
 mHealth APPs
  Suggestions2 (3.9)12–50
  Medical consultations1 (2.0)23
  Reminder2 (3.9)12–50
  Data monitoring/collection/store/transmit5 (9.8)12, 30, 32, 38, 39
 WPMDs
  Data monitoring/collection/store/transmit8 (15.7)23, 27, 28, 35, 36, 48–50
 Secondary intervention results
  Improved knowledge3 (5.9)1, 3, 4
  Improved adherence14 (27.5)4, 5, 7, 8, 12, 14, 18, 23, 24, 25, 36, 38, 45, 49
  Improved self-efficacy/self-care§13 (25.5)1, 3, 4, 7, 15, 18, 20, 35–38, 45, 50
  Improved behavior12 (23.5)1, 3, 6, 10, 15, 16, 18, 24, 30, 35, 41,45
  Improved satisfaction10 (19.6)2, 11, 12, 13, 27, 32, 34, 38, 41, 45
  Improved symptoms7 (13.7)6, 18, 22, 25, 34, 35, 41
  Improved quality of life10 (19.6)6, 16, 21, 22, 25, 27, 32, 35, 37, 41
  Improve complications6 (11.8)14, 15, 25, 28, 32, 33
  Changed bad habits1 (2.0)50
  Reduced costs¶2 (3.9)2–39
  • *Study ID: indicate the 1st to 51st study.

  • †Developing country: refers to countries with low levels of economy, technology, and people's living standards. Evaluation criteria mainly refer to the relatively low GDP per capita (GDP per capita) of the country.

  • ‡Medical consultations: patient–health care giver communication by phone, video, and so on.

  • §Improved self-efficacy/self-care: as evaluated by scale, such as diabetes self-efficacy scale, diabetes self-care activities scale, and so on.

  • ¶Reduced costs: it means that using mHealth can save the time for instruction than usual care, or save the time and money spent traveling to and from hospital, and so on.

  • HTN, hypertension; mHealth, mobile health; mHealth Apps, mobile health applications; MPCs, mobile phone calls; MPTMs, mobile phone text messages; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; WPMDs, wearable or portable monitoring devices.